These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7197436)

  • 1. [Results of a clinical study of cis-diamminodichloroplatinum].
    Gorbunova VA; Moroz LV
    Vestn Akad Med Nauk SSSR; 1981; (7):72-6. PubMed ID: 7197436
    [No Abstract]   [Full Text] [Related]  

  • 2. [Platinum derivatives in the clinical chemotherapy of malignant tumors].
    Gorbunova VA
    Vopr Onkol; 1982; 28(5):38-43. PubMed ID: 7201207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cis-dichlorodiammineplatinum (II): A new antitumor agent.
    Rainey JM
    Ariz Med; 1978 Jul; 35(7):462-3. PubMed ID: 678146
    [No Abstract]   [Full Text] [Related]  

  • 4. The future role of carboplatin.
    Ruckdeschel JC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):114-8. PubMed ID: 7992063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemetic therapy in patients treated with cisplatin chemotherapy.
    Roila F; Basurto C; Bracarda S; Del Favero A; Tonato M
    J Chemother; 1989 Jul; 1(4 Suppl):1281-5. PubMed ID: 16312866
    [No Abstract]   [Full Text] [Related]  

  • 6. Cisplatin: a clinical review. Part I--Current uses of cisplatin and administration guidelines.
    Cooley ME; Davis LE; DeStefano M; Abrahm J
    Cancer Nurs; 1994 Jun; 17(3):173-84. PubMed ID: 8055487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin: contemporary treatment approaches.
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):1-128. PubMed ID: 2762826
    [No Abstract]   [Full Text] [Related]  

  • 8. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts.
    Boulikas T
    Oncol Rep; 2004 Jul; 12(1):3-12. PubMed ID: 15201951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of cisplatin in combination with glutathione.
    Plaxe S; Freddo J; Kim S; Kirmani S; McClay E; Christen R; Braly P; Howell S
    Gynecol Oncol; 1994 Oct; 55(1):82-6. PubMed ID: 7959273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2004 Mar; 11(3):559-95. PubMed ID: 14767508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin: the future.
    Comis RL
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):109-13. PubMed ID: 7992062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
    Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
    Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant use of antioxidants may decrease the efficacy of cisplatin in cancer patients.
    Purnak T; Cengiz M; Altundag K
    Med Hypotheses; 2007; 68(5):1177. PubMed ID: 17134846
    [No Abstract]   [Full Text] [Related]  

  • 17. Cisplatin and related anticancer drugs: recent advances and insights.
    Barnes KR; Lippard SJ
    Met Ions Biol Syst; 2004; 42():143-77. PubMed ID: 15206102
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients.
    Arslan M; Evrensel T; Kurt E; Demiray M; Ercan I; Kanat O; Ozkan A; Manavoglu O
    Neoplasma; 2005; 52(1):43-5. PubMed ID: 15739025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal complications of cis-diamminedichloroplatinum.
    Nitschke R
    Ann Clin Lab Sci; 1981; 11(5):392-6. PubMed ID: 7199273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical experience with cisplatin resistance.
    Marshall JL; Andrews PA
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):415-29. PubMed ID: 7642471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.